Construction of pLLO vector encoding truncated form of Listeriolysin O as molecular adjuvant for DNA vaccine studies by Pouriayevali, Mohammad Hassan et al.
  Archives of Medical Laboratory Sciences  





Construction of pLLO vector encoding truncated form of 














1Department of Virology, School of Medical Sciences, Tarbiat Modares Univesity, Tehran, Iran 
2Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran 
 
Received: 13 September, 2016, Accepted:  1 December, 2016 
Abstract 
Background: The major problem of DNA vaccine is less immunogenicity of them verses other killed or live whole 
organism vaccines therefore adjuvants for use in this kind vaccines is very necessary. Genetic adjuvants with 
bacterial sources are an appropriate approach to modulate immune responses to DNA vaccines. Listeria 
Monocytogenes proteins such as Listeriolysin O (LLO) with CD4 and CD8 epitopes can be as an adjuvant to initiate 
both innate and adaptive immune responses if the protein cytotoxicity can be eliminated. Herein we constructed a 
truncated LLO plasmid as genetic adjuvant and tested it in combination with a DNA construct as a model vaccine.  
Materials and Methods: About 1340bp of the 5' end of whole LLO gene was amplified by PCR on DNA purified 
from Listeria Monocytogenes. Sequential sub cloning of truncated LLO into the Xho I/EcoRV sites of pcDNA3.1 
plasmid, downstream of CMV promoter was done. pLLO plasmid was transfected to HEK293T cell line by 
lipofection method. LLO protein expression from transiently transfected 293T cell lysates was confirmed by western 
blotting. Then the adjuvant activity of LLO in BALB/c mice model was analyzed using proliferation test.  
Results: Double digestion of pLLO plasmid with the enzymes that were applied for cloning led to the isolation of 
two fragments with expected sizes. The final plasmid was also confirmed following sequencing reactions. Moreover, 
expression of LLO was evidenced in transfected 293T cells, compared to non-transfected controls. In vivo study was 
shown, high significant proliferative responses in LLO co-immunization pattern.  
Conclusion: In the DNA vaccine study, LLO co-administration plasmid could be a suitable genetic adjuvant to 
enhance cellular immune response of vaccine. 
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The general goal of vaccination is the 
production of a robust immune response to the 
administered antigen able to give constant long term 
protection against infection (1). To attain this goal 
with DNA vaccine often requires the genetic 
adjuvants to improve the efficacy of vaccine (2). 
Whole alive or killed microorganisms are too 
harmful and toxic to be applied as adjuvants. 
Therefore, the bacteria-derived materials are using as  
a main potential source of adjuvants (1). This adjuvant 
activity is mediated through activation of Toll-like 
receptors that mediates the danger signals activating 
the host immune defense system (1). 
Listeria Monocytogenes is a gram-positive, 
facultative intracellular bacterium that  expresses a 
pore-forming toxin known as listeriolysin O (LLO) 
that  is essential for its pathogenesis and allows L. 
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monocytogenes to escape from endocytic  vesicle 
into the host cell cytosol, where the bacteria are able 
to multiply proficiently (3). LLO is a member of a 
large family of cholesterol-dependent cytotoxins 
(CDCs) which its activity is dependent on cholesterol 
linkage (4). LLO is of signaling molecules that 
promotes a variety of cellular responses involving 
production of cytokines, modifications of 
immunosuppression, alterations epigenetic and influx 
of calcium signaling  (5). This multifaceted feature of  
LLO is because of its ability to act as pathogen-
associated molecular patterns (PAMPs) and 
recognition by  Toll-like receptor 4 (TLR4) which is 
a pathogen recognition receptor (PRRs)(6). LLO 
improves antigen presentation in the context of MHC 
class I molecules and  enhances T cell-mediated 
immune responses when mixed or conjugated to 
antigens (7, 8). These activities appeared to be linked 
to different LLO domains, however, full length of 
LLO has toxicity effect which associated with its 
pore-forming. To overcome this obstacle, a 
detoxified, no hemolytic form of LLO (dtLLO), with 
deletion of c terminal of  protein sequence that are 
crucial for its binding to cholesterol was  constructed 
(9), This study has demonstrated that truncated LLO 
plasmid  could be cloned and expressed in 
mammalian cells without cytotoxicity to be used as a 
potent adjuvant in Vaccine design . 
Methods 
Plasmid construction. In this study, Listeria 
Monocytogenes (serotype 2) were purchased from 
Persian Type Culture Collection and bacterial 
genomic DNA was extracted according to the manual 
of high pure PCR template preparation kit (Roche, 
Germany). To amplify the LLO truncated form (5 to 
415 aa of LLO full length protein), we amplified 
LLO using FLLO XhoI and R1LLO primers for fist 
PCR then FLLO XhoI and R2LLOECoRV primers 
for nested PCR (table 1). The two PCR reaction (25 
μl, total) included 1ug of extracted genome in first 
PCR and 1ul of prior PCR product in the second 
PCR, 10 pmol of each primers ,2.5mM Mgcl2, 
0.2mM dNTP and 1 U of Pfu DNA polymerase, and 
after the initial denaturation at 95 °C for 5 min, 
thermal program of 95 °C for 15 sec, 55 °C for 60 
sec and 72 °C for 120 sec was applied for 40 cycles 
and final extension at 72°C for 10 min then the second 
PCR product was visualized under a UV trans 
illuminator in 1.5% agarose gel containing safe stain 
DNA, and purified with PCR product purification Kit 
(Roche, Germany). The purified PCR product and 
pcDNA3.1(Invitrogen, CA, United States) were 
digested with XhoI and EcoRV restriction enzyme and 
then the PCR product was subcloned into the XhoI/ 
EcoRV sites of pcDNA3.1 under cytomegalovirus 
(CMV) promoter(figure 1) and transformed into DH5α 
Ecoli strain competent cell. The pcDNA3.1-LLO 
(pLLO) construct was confirmed by restriction 
enzyme study and bidirectional sequencing. 
Expression of recombinant truncated LLO 
fragment. Expression of LLO fragment was analyzed 
in transfected 293T cells with the pLLO by the 
turbofect kit (Thermo Scientific, CA). One day after 
transfection, the medium was changed with complete 
medium to grow for 48 hours. Finally, the transfected 
cells were collected to detect the LLO truncated 
protein. The un-transfected cells served as the negative 
control. The collected cells were washed two times in 
PBS and lysed with lysis buffer (1% Nonidet P-40, 10 
mg/L- phenyl methyl sulfonyl fluoride 50 mM-tris Cl, 
pH 8.0) for 0.5 hr on ice and then the lysates were 
centrifuged at 800 g for 15 minutes. The supernatants 
were collected to be evaluated by the western-blot 
method. 
Western Blotting. The recombinant LLO 
protein, were resolved by 15% gel. The protein bands 
were transferred to nitrocellulose membranes 
(Amersham, United Kingdom). Subsequently, 
blocking buffer (3% non-fat skimmed plus 0.05% 
tween 20) was utilized for 1.5 hr at room temperature 
to block membrane. The membrane was incubated 
with 1:2000 diluted of Anti-Listeriolysin (LLO) 
antibody (ab43018 Abcam USA) in blocking buffer as 
the primary antibody for two hr at room temperature, 
then washed three times for five minutes with TBST 
(tris buffered saline containing 0.1% Tween 20). After 
washing, the membrane was incubated with HRP-
conjugated anti rabbit against IgG (Invitrogen, 
Germany), diluted at 1:10000 in TBST for one hr at 
room temperature and then, washing was performed as 
mentioned before. Chemiluminescent HRP substrate 
(Amersham, UK) was added to the membrane for 
seven minutes at room temperature. In the following, 
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the produced light was recorded on a film. 
Protocol of Immunization. Female BALB/c 
(H-2d) mice , 6 week old were immunized i.d in 
three times with two weeks interval using by 100 µg 
of purified plasmids pLLO, pc-NS3 ( HCV Non-
structural protein 3 plasmid as immunogenic plasmid 
control) (10) or  pLLO plus pc-NS3 (co-
administration) . All experiments were approved by 
accordance with the national experimental guidelines 
and ethics council (ethics number: D52/639). 
Cell Proliferation Assays. Two weeks post-
immunization, five mice of each group were 
sacrificed according animal ethics protocols and 
spleens were harvested aseptically. Proliferation 
assays were performed by using the BrdU(5-bromo-2 
deoxyuridine, Roche, Germany) ELISA Roche cell 
proliferation kit. Briefly, The RBC lysed splenocytes 
were cultured as triplicates (1 × 106 cells/well) in a 
24-well culture plate stimulated with 3 µg/mL of 
recombinant NS3 protein(rNS3). Con A 
(concanavalin A, 5 μg/mL; Sigma, USA) was added 
in positive wells to ensure the cells were healthy and 
un-stimulated wells were used as negative controls. 
After 60 hours incubation, 20 µL/well BrdU solution 
was added and re-incubated for 12 hours at 37°C, and 
finally the proliferation analysis was performed 
according to the roche BrdU protocol (Roche, 
Germany). Stimulation index was calculated by 
dividing the OD rNS3 stimulated wells to OD un-
stimulated blank for each group. 
Results 
PCR amplification and construction of 
recombinant plasmid. The LLO PCR products were 
analyzed on 1% agarose gel in parallel with 1kb 
DNA ladder marker. The expected 1355 bp PCR 
product fragment was observed. The XhoI 
andEcoRV digested pcDNA3.1 plasmid and LLO 
PCR product were purified by gel extraction method 
(figure 2A). The LLO PCR product was ligated to 
pcDNA3.1 plasmid then the ligated plasmid (figure 
1) was transformed into E.coli DH5α competent cell. 
The recombinant plasmid was confirmed by 
restriction enzyme analysis (figure 2B) and 
sequencing analysis. 
Expression of the LLO in mammalian cells. 
During 48 hours after transfection the cells were 
monitored for cell cytotoxicity. No remarkable 
cytotoxic effect was seen comparing to control. The 
expression of LLO truncated gene was evaluated in 
transfected HEK293T cells by western blotting using 
Anti-Listeriolysin (LLO) antibody (Abcam USA). 
Mock-transfected HEK293T cell was served as the 
negative control. In western blot result was shown The 
expression of LLO fragment in transfected HEK293T 
lysate and no expression in the negative control 
HEK293T cells (figure 3).  
Cell Proliferation Assay. The mice groups 
were immunized i.d. with 100 μg pLLO alone, 100 μg 
pc-NS3 alone, or 100 μg pLLO plus 100 μg pc-NS3. 
The immunization was performed in three times with 
two weeks interval. The specific proliferation was 
measured 2weeks following last immunization. To 
analyze proliferative responses, splenocytes of 
immunized mice were stimulated with NS3 protein 
while incorporation of BrdU into the stimulated 
splenocytes was detected by ELISA. As shown in 
Figure 4, NS3-specific proliferations were 
significantly augmented in immunized concurrently 
with pc-NS3 and pLLO group compared with pLLO 
alone or pc-NS3 alone (P < 0.05). 
Discussion 
The relatively low efficacy of DNA vaccines in 
inducing immune responses, especially in large animal 
species has impaired their practical use. Therefore 
considerable effort expended on improving DNA 
vaccine, using different adjuvants(2, 11, 12). The 
construction of genetic adjuvants of infectious agents 
are another alternative approach when used as co-
delivered vector in order to modulate immune 
responses to DNA vaccines. Listeria Monocytogenes 
proteins such as Listeriolysin O (LLO)which has some 
CD4 and CD8 epitopes can be act as an adjuvant to 
initiate both CD4 + and CD8 + immune responses(13), 
trigger signals to  activate  deferent  aspects  of  the  
immune  systems  for antitumor activity(14), reduce 
tolerance of “self-/tumor-associated  antigens” and 
expand the effects of “non-self-foreign” antigens as do 
classical adjuvants. Additionally, purified LLO when 
mixed with foreign proteins and administered to 
mammalian cells, can transfer protein in cytosol and 
has been exploited for delivery to host cells both in 
vitro and in vivo. In general, LLO protein contains all 
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key factors of an ideal adjuvant but  full length of 
LLO protein has a strong apoptogenic aspect that 
induces death in activated T cells and inhibit their 
responses (15). Moreover, this protein causes cell 
death and other marked negative effects in dendritic 
cells that inhibits antigen presentation (16, 17). 
Previous study was shown that high innate and 
adaptive immunogenic effects of LLO protein is 
induced by a separate portion of its cytotoxic activity  
domain(13). Currently, the crystal structure study of 
LLO has been shown which rod-like whole LLO 
protein has four distinguished domains, referred to as 
D1 to D4 detail(18). Among of all domains, D4 with 
 
 
Table 1: Primers sequence, PCR product size and temperature melting of primers 
Tm ( ˚c)  
PCR Product 
size (bp)  
5’→3’ Primers  
60 1333  
CGC CTC GAG ACC ATG CTA GTT TTT ATT ACA C  FLLOXhoI Forward 
1st 
GTG GTG GTG GTG ATC ATA ATT TAC TTC ATC C  R1LLO Reverse 1 
60 1355  
CGC CTC GAG ACC ATG CTA GTT TTT ATT ACA C  FLLOXhoI Forward 
2nd ATA G A TA T C ATTA ATG ATG GTG GTG GTG 
GTG ATC  




Figure 1. Schematic presentation of recombinant pLLO. 
 
 
Figure 2. Purified PCR amplification of LLO and restriction analysis  for confirmation of pLLO. A) Lane 1: Purified PCR Product of LLO 
truncated fragment(5 to 415 aa of LLO  full length protein) which is 1355bp in size, Lane 2: 1kb  DNA ladder marker.B) Lane 1: pcDNA3.1 
plasmid, Lane 2: 1kb  DNA ladder marker, Lane 3: pcDNA3.1-LLO(pLLO) digested by EcoRV (linear pLLO plasmid), Lane 4: pLLO 
digested by XhoI and EcoRV restriction enzymes. 
 
 
Figure 3. Analysis of truncated LLO protein Expression by 








































Figure 4. Specific cell proliferation assay: Two weeks after last 
immunization, The Splenocytes of  three immunized mice groups 
were resuspended in RPMI 1640 containing  10% FBS and the 
rNS3-specific proliferation following stimulation with 3 μg/ml 
recombinant NS3 was determined by cell proliferation ELISA, BrdU 
colorimetric kit. The mean stimulation index values are shown for 
each group. (* indicates statistical significance, P value < 0.05).  
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conserved structural motif in the C terminal region, is 
responsible to membrane binding and cytotoxic 
activity(19). Previous study was shown that truncated 
form of LLO (including domains 1-3), lacking 
domain 4, is the main region for the induction of 
proinflammatory cytokines and innate immune 
response(20). Carrero et al. studies have shown that 
conversion of tryptophan to alanine at residues 491 
and 492 led to a reduction in cytolytic and hemolytic 
effects to 95% without a significant decrease in the 
binding, processing and presentation of 
immunodominant peptides to T cells.  Thus it can be 
concluded that LLO immunogenicity is independent 
of cytotoxic activities (13). 
Conclusion 
Our result indicated that pLLO gene fragment 
encoding only domains 1-3 of whole LLO gene was 
constructed successfully and cloning accuracy was 
confirmed by restriction enzyme study and 
sequencing. Then the ability of this plasmid to 
express on mammalian cell line was confirmed by 
western blotting assay. The NS3 specific 
proliferation results, following mice immunization 
shown in figure 4 demonstrates the significant high 
proliferation response in pc-NS3/pLLO group 
compared to pc-NS3 group. According to this 
finding, pLLO as co-administration plasmid could be 
a potent genetic adjuvant to enhance immune 
response of DNA vaccine. 
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